Market Report, "Cytograft Tissue Engineering, Inc. - Product Pipeline Analysis, 2013 Update", Published
Cytograft Tissue Engineering, Inc. (CTE) is a genetic engineering company. The company develops cell-based solutions for the treatment of cardiovascular diseases. It has developed a regenerative medicine platform, Tissue Engineering by Self-Assembly, or TESA. CTE's product portfolio includes tissue engineered blood vessel, covered stent, patch, percutaneous bypass and valve. The company's technologies include sheet-based tissue engineering, thread-based tissue engineering and particle-based tissue engineering. It repairs diseased cardiovascular tissues and organs. CTE transforms cardiovascular medicine by developing cell-based therapies to repair...
View full press release